166 related articles for article (PubMed ID: 10395861)
21. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
22. Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases.
Blanco MT; Hurtado C; Pérez-Giraldo C; Morán FJ; González-Velasco C; Gómez-García AC
Med Mycol; 2003 Apr; 41(2):167-70. PubMed ID: 12964850
[TBL] [Abstract][Full Text] [Related]
23. "In vitro" antifungal activity of protease inhibitors.
Mata-Essayag S; Magaldi S; Hartung de Capriles C; Deibis L; Verde G; Perez C
Mycopathologia; 2001; 152(3):135-42. PubMed ID: 11811641
[TBL] [Abstract][Full Text] [Related]
24. Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
Trabocchi A; Mannino C; Machetti F; De Bernardis F; Arancia S; Cauda R; Cassone A; Guarna A
J Med Chem; 2010 Mar; 53(6):2502-9. PubMed ID: 20184325
[TBL] [Abstract][Full Text] [Related]
25. The impact of HIV-protease inhibitors on opportunistic parasites.
Pozio E; Morales MA
Trends Parasitol; 2005 Feb; 21(2):58-63. PubMed ID: 15664527
[TBL] [Abstract][Full Text] [Related]
26. The secreted aspartic proteinases as a new target in the therapy of candidiasis.
Bein M; Schaller M; Korting HC
Curr Drug Targets; 2002 Oct; 3(5):351-7. PubMed ID: 12182226
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis.
Lian CH; Liu WD
Mycoses; 2007 Sep; 50(5):383-90. PubMed ID: 17714358
[TBL] [Abstract][Full Text] [Related]
28. Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis.
Asencio MA; Garduño E; Pérez-Giraldo C; Blanco MT; Hurtado C; Gómez-García AC
Chemotherapy; 2005 Aug; 51(5):252-5. PubMed ID: 16088122
[TBL] [Abstract][Full Text] [Related]
29. Lack of ritonavir antifungal effect in vitro.
Diz P; Ocampo A; Iglesias I; Otero I
Antimicrob Agents Chemother; 1999 Apr; 43(4):997. PubMed ID: 10200872
[No Abstract] [Full Text] [Related]
30. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.
Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301
[TBL] [Abstract][Full Text] [Related]
31. High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women.
de Bernardis F; Mondello F; Scaravelli G; Pachì A; Girolamo A; Agatensi L; Cassone A
J Clin Microbiol; 1999 May; 37(5):1376-80. PubMed ID: 10203490
[TBL] [Abstract][Full Text] [Related]
32. Antileishmanial activity of HIV protease inhibitors.
Savoia D; Allice T; Tovo PA
Int J Antimicrob Agents; 2005 Jul; 26(1):92-4. PubMed ID: 15955671
[TBL] [Abstract][Full Text] [Related]
33. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.
Maninder J; Usha A
J Commun Dis; 2008 Sep; 40(3):177-81. PubMed ID: 19245155
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Candida parapsilosis infection of an in vitro reconstituted human oral epithelium.
Silva S; Henriques M; Oliveira R; Azeredo J; Malic S; Hooper SJ; Williams DW
Eur J Oral Sci; 2009 Dec; 117(6):669-75. PubMed ID: 20121929
[TBL] [Abstract][Full Text] [Related]
35. Antiretrovirals as antimalarial agents.
Skinner-Adams TS; McCarthy JS; Gardiner DL; Hilton PM; Andrews KT
J Infect Dis; 2004 Dec; 190(11):1998-2000. PubMed ID: 15529265
[TBL] [Abstract][Full Text] [Related]
36. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo.
Chami N; Bennis S; Chami F; Aboussekhra A; Remmal A
Oral Microbiol Immunol; 2005 Apr; 20(2):106-11. PubMed ID: 15720571
[TBL] [Abstract][Full Text] [Related]
37. Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.
Palmeira VF; Kneipp LF; Alviano CS; dos Santos AL
Res Microbiol; 2006 Nov; 157(9):819-26. PubMed ID: 16959473
[TBL] [Abstract][Full Text] [Related]
38. Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans.
Schaller M; Krnjaic N; Niewerth M; Hamm G; Hube B; Korting HC
J Med Microbiol; 2003 Mar; 52(Pt 3):247-249. PubMed ID: 12621090
[TBL] [Abstract][Full Text] [Related]
39. Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans.
Santos AL; Braga-Silva LA
Mini Rev Med Chem; 2013 Jan; 13(1):155-62. PubMed ID: 23256485
[TBL] [Abstract][Full Text] [Related]
40. Multiple effects of amprenavir against Candida albicans.
Braga-Silva LA; Mogami SS; Valle RS; Silva-Neto ID; Santos AL
FEMS Yeast Res; 2010 Mar; 10(2):221-4. PubMed ID: 20030734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
